CSIMarket
 


Biocryst Pharmaceuticals Inc   (BCRX)
Other Ticker:  
 
 

BCRX's Revenue Growth by Quarter and Year

Biocryst Pharmaceuticals Inc 's Revenue results by quarter and year




BCRX Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 93.40 79.55 47.16 6.10
III Quarter September 86.74 75.83 40.99 2.87
II Quarter June 82.49 65.53 49.96 4.82
I Quarter March 68.78 49.92 19.06 39.73
FY   331.41 270.83 157.17 53.52



BCRX Revenue fourth quarter 2023 Y/Y Growth Comment
Biocryst Pharmaceuticals Inc reported Revenue increase of 17.41% year on year in the fourth quarter 2023, to $ 93.40 millions, this is lower than Biocryst Pharmaceuticals Inc 's recent average Revenue rise of 68.91%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 10 other companies have achieved higher Revenue growth. While Biocryst Pharmaceuticals Inc ' s Revenue growth of 17.41% ranks overall at the positon no. 538 in the fourth quarter 2023.




BCRX Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 17.41 % 68.68 % 673.11 % 242.7 %
III Quarter September 14.39 % 85 % 1328.22 % 97.93 %
II Quarter June 25.88 % 31.16 % 936.51 % -18.17 %
I Quarter March 37.78 % 161.91 % -52.03 % 1355.31 %
FY   22.37 % 72.32 % 193.67 % 351.65 %

Financial Statements
Biocryst Pharmaceuticals Inc 's fourth quarter 2023 Revenue $ 93.40 millions BCRX's Income Statement
Biocryst Pharmaceuticals Inc 's fourth quarter 2022 Revenue $ 79.55 millions Quarterly BCRX's Income Statement
New: More BCRX's historic Revenue Growth >>


BCRX Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 7.68 % 4.91 % 15.05 % 112.54 %
III Quarter September 5.15 % 15.72 % -17.95 % -40.46 %
II Quarter June 19.93 % 31.27 % 162.12 % -87.87 %
I Quarter March -13.54 % 5.85 % 212.46 % 2132.02 %
FY (Year on Year)   22.37 % 72.32 % 193.67 % 351.65 %




Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #100
Overall #538

Revenue Y/Y Growth Statistics
High Average Low
472.31 % 68.91 % -60.45 %
(Mar 31 2022)   (Jun 30 2019)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #11
Healthcare Sector #100
Overall #538
Revenue Y/Y Growth Statistics
High Average Low
472.31 % 68.91 % -60.45 %
(Mar 31 2022)   (Jun 30 2019)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Biocryst Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2138.03 % 76.05 % -88.36 %
(Dec 31 2019)  


BCRX's IV. Quarter Q/Q Revenue Comment
Biocryst Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue increase of 7.68% quarter on quarter, to $ 93.40 millions.

Albeit the IV. Quarter 2023 BCRX's Revenue quarter on quarter growth was lower than the regular of 76.05 %, that has been still good sign, as the current expension, eclipses the 4.91% Revenue growth in the same quarter a year ago

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Biocryst Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 554.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #93
Overall #554
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #14
Healthcare Sector #93
Overall #554
Revenue Q/Q Growth Statistics
High Average Low
2138.03 % 76.05 % -88.36 %
(Dec 31 2019)  


BCRX's IV. Quarter Q/Q Revenue Comment
Biocryst Pharmaceuticals Inc achieved in the IV. Quarter 2023 below company average Revenue increase of 7.68% quarter on quarter, to $ 93.40 millions.

Albeit the IV. Quarter 2023 Revenue quarter on quarter growth was lower than the regular , this has been still good sign, as the current expension, transcends the 4.91% surge in the IV. Quarter 2022

Within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Revenue quarter on quarter growth. While Biocryst Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 554.


Biocryst Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 331.41 $ 317.56 $ 306.64 $ 289.68 $ 270.83
Y / Y Revenue Growth (TTM) 22.37 % 33.18 % 50.6 % 54.06 % 72.31 %
Year on Year Revenue Growth Overall Ranking # 82 # 234 # 53 # 47 # 51
Seqeuential Revenue Change (TTM) 4.36 % 3.56 % 5.85 % 6.96 % 13.58 %
Seq. Revenue Growth (TTM) Overall Ranking # 538 # 560 # 875 # 838 # 398




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Biocryst Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 331 millions, company would post below average annual Revenue growth of 13.58% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Biocryst Pharmaceuticals Inc 's Revenue growth from the 86.74% growth in Sep 30 2023.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 82, from total ranking in previous quarter at 234.

Revenue TTM Q/Q Growth Statistics
High Average Low
472.31 %
68.91 %
-60.45 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 22
Overall # 82

Revenue TTM Y/Y Growth Statistics
High Average Low
472.31 %
68.91 %
-60.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 100
S&P 500 # 538
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2023 period, Biocryst Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 331 millions, company would post below average annual Revenue growth of -60.45% year on year, if the fiscal year would end at Dec 31 2023.
A slow-down in the Biocryst Pharmaceuticals Inc 's Revenue growth from the 86.74% growth in Sep 30 2023.

Within the Healthcare sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 82, from total ranking in previous quarter at 234.

Revenue TTM Q/Q Growth Statistics
High Average Low
472.31 %
68.91 %
-60.45 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 22
Overall # 82

Revenue TTM Y/Y Growth Statistics
High Average Low
472.31 %
68.91 %
-60.45 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 11
Sector # 100
S&P 500 # 538




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BCRX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for BCRX's Competitors
Revenue Growth for Biocryst Pharmaceuticals Inc 's Suppliers
Revenue Growth for BCRX's Customers

You may also want to know
BCRX's Annual Growth Rates BCRX's Profitability Ratios BCRX's Asset Turnover Ratio BCRX's Dividend Growth
BCRX's Roe BCRX's Valuation Ratios BCRX's Financial Strength Ratios BCRX's Dividend Payout Ratio
BCRX's Roa BCRX's Inventory Turnover Ratio BCRX's Growth Rates BCRX's Dividend Comparisons



Companies with similar Revenue increase for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Biofrontera Inc 30.41%$ 30.414 millions
Conmed Corporation30.37%$ 30.366 millions
Schrodinger Inc 30.33%$ 30.327 millions
Sophia Genetics Sa30.18%$ 30.179 millions
Penumbra Inc 28.69%$ 28.688 millions
Eli Lilly And Company28.10%$ 28.097 millions
Axonics Inc 27.92%$ 27.920 millions
Dexcom Inc 26.94%$ 26.938 millions
Halozyme Therapeutics Inc 26.75%$ 26.746 millions
Medpace Holdings Inc 26.47%$ 26.466 millions
Pulmonx Corporation26.12%$ 26.120 millions
Maxcyte inc 26.09%$ 26.087 millions
Progyny Inc 26.04%$ 26.045 millions
United Therapeutics Corporation25.07%$ 25.066 millions
Neurocrine Biosciences Inc 25.05%$ 25.049 millions
Aquestive Therapeutics Inc 23.63%$ 23.629 millions
Sotera Health Company23.61%$ 23.612 millions
Xoma Corporation23.35%$ 23.351 millions
Vericel Corporation23.35%$ 23.346 millions
Inari Medical Inc 22.95%$ 22.949 millions
Exact Sciences Corporation22.81%$ 22.810 millions
Veracyte inc 22.29%$ 22.295 millions
Guardant Health Inc 22.19%$ 22.195 millions
Cytek Biosciences Inc 22.06%$ 22.058 millions
Alpha Pro Tech Ltd 21.78%$ 21.783 millions
Protalix Biotherapeutics inc 21.69%$ 21.690 millions
Si bone inc 21.28%$ 21.278 millions
Ensign Group Inc21.10%$ 21.104 millions
Aadi Bioscience Inc 21.03%$ 21.025 millions
Privia Health Group Inc 20.97%$ 20.966 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com